Pediatrics. 2014 Dec;134(6):1230-3. doi: 10.1542/peds.2014-2811.
Routine use of the pneumococcal conjugate vaccines (PCV7 and PCV13), beginning in 2000, has resulted in a dramatic reduction in the incidence of invasive pneumococcal disease (IPD) attributable to serotypes of Streptococcus pneumoniae contained in the vaccines. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics recommend the expanded use of PCV13 in children 6 through 18 years of age with certain conditions that place them at elevated risk of IPD. This statement provides recommendations for the use of PCV13 in children 6 through 18 years. A single dose of PCV13 should be administered to certain children in this age group who are at elevated risk of IPD. Recommendations for the use of PCV13 in healthy children and for pneumococcal polysaccharide vaccine (PPSV23) remain unchanged.
自2000年起常规使用肺炎球菌结合疫苗（PCV7和PCV13），已使疫苗中包含的肺炎链球菌血清型所致侵袭性肺炎球菌疾病（IPD）的发病率大幅降低。疾病控制与预防中心免疫实践咨询委员会及美国儿科学会建议，对于6至18岁患有某些使其患IPD风险升高疾病的儿童，扩大使用PCV13。本声明提供了6至18岁儿童使用PCV13的建议。应给该年龄组中某些患IPD风险升高的儿童接种一剂PCV13。健康儿童使用PCV13及肺炎球菌多糖疫苗（PPSV23）的建议保持不变。
